Arun Sanyal, EASL ILC 2021: Icosabutate ICONA Trial in NASH

In Part 2, we speak with Prof. Arun Sanyal (Virginia Commonwealth University, Richmond, VA, USA) about the interim analysis from the ICONA trial (NCT04052516) which is designed to investigate icosabutate as a potential therapeutic approach to address liver- and cardiovascular-related morbidity and mortality in patients with NASH. His abstract entitled ‘Icosabutate, a novel structurally engineered […]

Claudia Fox, ENDO 2021: Exenatide for Weight Loss Maintenance in Adolescents

We were delighted to talk to Professor Claudia Fox (University of Minnesota, Minneapolis, MN, US) around the use of exenatide for weight loss maintenance among adolescents with severe obesity. ‘Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial.‘ (PRESENTATION NUMBER: OR02-4) was presented at the ENDO 2021 Virtual Annual […]

Domenica M. Rubino, ENDO 2021: Findings from the STEP 4 Study

It was a pleasure to talk to Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA, US) around the effect of once-weekly semaglutide on weight loss maintenance in overweight or obese adults. ‘Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4).‘ (PRESENTATION […]

Luca Valenti, NAFLD Summit 2021: The Latest Advances in NAFLD

TouchENDOCRINOLOGY joins Prof Luca Valenti (University of Milan, Italy) at the Digital NAFLD Summit 2021 to discuss his hopes for the conference and the most exciting new developments in the field of non-alcoholic fatty liver disease (NAFLD). Questions Could you give us an overview of the clinical spectrum of non-alcoholic fatty liver disease (NAFLD) and […]

Acromegaly Due to McCune–Albright Syndrome

US Endocrinology. 2020;16(1):47–50 DOI: https://doi.org/10.17925/USE.2020.16.1.47

McCune–Albright syndrome (MAS) is a genetic disorder first described by McCune1 and Albright2  in the 1930s as a triad of polyostotic fibrous dysplasia, café-au-lait spots, and precocious puberty (Figure 1). Since then, other hyperfunctioning endocrinopathies have been described in MAS, including hyperthyroidism, Cushing’s syndrome, hypophosphatemic osteomalacia, and acromegaly.3 Patients with MAS display mosaicism as the disease results […]

Pheochromocytoma Due to TMEM127 Mutation – The Importance of Genetic Testing for Clinical Decision

European Endocrinology. 2020;16(1):72-4

Catecholamine-secreting tumours that arise from chromaffin cells of the adrenal medulla and the sympathetic ganglia are respectively referred to as pheochromocytomas and paragangliomas. The term paraganglioma is also used for tumours derived from parasympathetic tissue in the head and neck, most of which do not produce catecholamines.1 The classic triad of symptoms in patients with […]

Diabetic Polyneuropathy – Advances in Diagnosis and Intervention Strategies

European Endocrinology. 2020;16(1):15–20

Diabetic polyneuropathy (DPN) is the most common microvascular complication of diabetes, affecting approximately 50% of all people with diabetes (type 1 diabetes [T1D] and type 2 diabetes [T2D]).1 DPN is a major cause of disability due to sensory loss, gait instability and fall‐related injuries,1–5 and is the strongest risk factor for diabetic foot ulceration and amputation.1–4 Up to […]

Cost Comparison of Flash Continuous Glucose Monitoring with Self-monitoring of Blood Glucose in Adults with Type 1 or Type 2 Diabetes Using Intensive Insulin—From a US Private Payer Perspective

US Endocrinology. 2020;16(1):24–30 DOI: https://doi.org/10.17925/USE.2020.16.1.24

Unmet needs for glucose monitoring in people with diabetes mellitus using intensive insulin Glucose monitoring is essential for people using intensive insulin to inform adjustments to the treatment and management of diabetes. Evidence suggests many people do not adhere to the recommended testing frequency with self-monitoring of blood glucose (SMBG). In the USA, it was […]